Sunset, Louisiana (PRWEB) May 27, 2014
EnLyte with Delta Folate was launched in 2011. An advanced generation prescription folate therapy, it is promoted by JayMac Pharmaceuticals mainly to the psychiatric and obgyn segments. It is used in conditions related to folate deficiency, including Major Depressive Disorder (MDD) and prevention of neural tube defects (NTDs) in pregnancy.
Prior to this launch, there was only one folate therapy in this space, and the introduction of this new choice has been met with steady support from the medical community. According to Psychiatric Nurse Practitioner, Fran Saponaro, "I use EnLyte and find my patients feel it is an important part of their medication regime." it is priced competitively, dosed once a day, and is safe for use by pregnant and lactating women.
The company recently presented at the annual meeting of the American Psychiatric Association, as well as the NEI Psychopharmacology Update, and plans to attend all of the most important professional conferences around the nation.
EnLyte is an orally-administered prescription folate-containing product for the clinical dietary management of depression related to suboptimal folate levels associated with metabolic imbalances in transformylation and/or methylation biochemistry. To learn more, visit http://www.EnLyteRx.Com.